What is the stock price of hgh

HomeMarketsDiscoverWatchlistPortfoliosScreener

Summary of all time highs, changes and price drops for Heartland Group Holdings

Historical stock prices
Current Share Price	NZ$1.76
52 Week High	NZ$2.59
52 Week Low	NZ$1.72
Beta	1.14
1 Month Change	-6.38%
3 Month Change	-7.85%
1 Year Change	-23.14%
3 Year Change	9.32%
5 Year Change	-3.30%
Change since IPO	104.65%

Sep 07

Heartland Group Holdings Limited announced that they will report fiscal year 2022 final results at 10:00 AM, NZST - New Zealand Standard on Sep 28, 2022

Sep 06

Heartland Group Holdings Limited announced that they will report fiscal year 2022 final results at 10:00 AM, NZST - New Zealand Standard on Sep 28, 2022

Aug 30

After last week's 16% share price decline to NZ$1.79, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 11x in the Banks industry in Oceania. Total returns to shareholders of 35% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at NZ$2.60 per share.

Aug 24

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Aug 24

Over the last 90 days, the stock is down 11%. The fair value is estimated to be NZ$2.60, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Earnings per share has grown by 7.2%. For the next 3 years, revenue is forecast to grow by 8.9% per annum. Earnings is also forecast to grow by 9.9% per annum over the same time period.

Aug 24

Heartland Group Holdings Limited has completed a Follow-on Equity Offering in the amount of NZD 130 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 72,222,222 Price\Range: NZD 1.8 Discount Per Security: NZD 0.018 Transaction Features: Subsequent Direct Listing

	HGH	NZ Banks	NZ Market
7D	-2.8%	-1.0%	-1.4%
1Y	-23.1%	-8.0%	-17.0%

See full shareholder returns

Return vs Industry: HGH underperformed the NZ Banks industry which returned -8% over the past year.

Return vs Market: HGH underperformed the NZ Market which returned -17% over the past year.

Is HGH's price volatile compared to industry and market?

HGH volatility
HGH Average Weekly Movement	4.5%
Banks Industry Average Movement	3.7%
Market Average Movement	3.8%
10% most volatile stocks in NZ Market	8.0%
10% least volatile stocks in NZ Market	2.7%

Stable Share Price: HGH is not significantly more volatile than the rest of NZ stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: HGH's weekly volatility (4%) has been stable over the past year.

Heartland Group Holdings Limited provides various financial services in New Zealand and Australia. The company offers savings accounts, term deposits, and direct and business call accounts. It also provides home loans, business loans, term loans, revolving credit, car loans, and reverse mortgage lending and other financial services.

How do Heartland Group Holdings's earnings and revenue compare to its market cap?

HGH fundamental statistics
Market Cap	NZ$1.24b
Earnings (TTM)	NZ$95.13m
Revenue (TTM)	NZ$253.79m

Is HGH overvalued?

See Fair Value and valuation analysis

Key profitability statistics from the latest earnings report

HGH income statement (TTM)
Revenue	NZ$253.79m
Cost of Revenue	NZ$0
Gross Profit	NZ$253.79m
Other Expenses	NZ$158.67m
Earnings	NZ$95.13m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Sep 27, 2022

Earnings per share (EPS)	0.13
Gross Margin	100.00%
Net Profit Margin	37.48%
Debt/Equity Ratio	319.6%

How did HGH perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Is HGH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score 3/6

Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Which metric is best to use when looking at relative valuation for HGH?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for HGH. This is calculated by dividing HGH's market cap by their current preferred multiple.

What is HGH's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	NZ$1.24b

HGH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.

Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	1.5x

How does HGH's PE Ratio compare to its peers?

The above table shows the PE ratio for HGH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.

Company	PE	Estimated Growth	Market Cap
Peer Average	9.9x
	13.5x	n/a	NT$23.5b
BJTM Bank Pembangunan Daerah Jawa Timur	7x	19.3%	Rp10.8t
	5.1x	9.8%	zł3.3b
RCB Rizal Commercial Banking	4.8x	n/a	₱42.7b
HGH Heartland Group Holdings	13.1x	8.5%	NZ$1.2b

Price-To-Earnings vs Peers: HGH is expensive based on its Price-To-Earnings Ratio (13.1x) compared to the peer average (9.9x).

How does HGH's PE Ratio compare vs other companies in the Global Banks Industry?

Price-To-Earnings vs Industry: HGH is expensive based on its Price-To-Earnings Ratio (13.1x) compared to the Global Banks industry average (9.1x)

What is HGH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HGH PE Ratio vs Fair Ratio.

Fair Ratio
Current PE Ratio	13.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate HGH's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of HGH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HGH (NZ$1.76) is trading below our estimate of fair value (NZ$2.64)

Significantly Below Fair Value: HGH is trading below fair value by more than 20%.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

How is Heartland Group Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score 3/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

8.5%

Forecasted annual earnings growth

Earnings vs Savings Rate: HGH's forecast earnings growth (8.5% per year) is above the savings rate (2.1%).

Earnings vs Market: HGH's earnings (8.5% per year) are forecast to grow faster than the NZ market (5.9% per year).

High Growth Earnings: HGH's earnings are forecast to grow, but not significantly.

Revenue vs Market: HGH's revenue (7.6% per year) is forecast to grow faster than the NZ market (5.6% per year).

High Growth Revenue: HGH's revenue (7.6% per year) is forecast to grow slower than 20% per year.

Future ROE: HGH's Return on Equity is forecast to be low in 3 years time (11.4%).

How has Heartland Group Holdings performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

8.3%

Historical annual earnings growth

Quality Earnings: HGH has a high level of non-cash earnings.

Growing Profit Margin: HGH's current net profit margins (37.5%) are higher than last year (36.8%).

Earnings Trend: HGH's earnings have grown by 8.3% per year over the past 5 years.

Accelerating Growth: HGH's earnings growth over the past year (9.3%) exceeds its 5-year average (8.3% per year).

Earnings vs Industry: HGH earnings growth over the past year (9.3%) exceeded the Banks industry 1.2%.

High ROE: HGH's Return on Equity (11.8%) is considered low.

How is Heartland Group Holdings's financial position? (This company is analysed differently as a bank or financial institution)

Financial Health Score

3/6

Financial Health Score 3/6

Asset Level
Allowance for Bad Loans
Low Risk Liabilities
Loan Level
Low Risk Deposits
Level of Bad Loans

Asset Level: HGH's Assets to Equity ratio (8.8x) is low.

Allowance for Bad Loans: HGH has a low allowance for bad loans (38%).

Low Risk Liabilities: 57% of HGH's liabilities are made up of primarily low risk sources of funding.

Loan Level: HGH has an appropriate level of Loans to Assets ratio (87%).

Low Risk Deposits: HGH's Loans to Deposits ratio (171%) is high.

Level of Bad Loans: HGH has a high level of bad loans (2.2%).

What is Heartland Group Holdings's current dividend yield, its reliability and sustainability?

Dividend Score 5/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

6.25%

Current Dividend Yield

Notable Dividend: HGH's dividend (6.25%) is higher than the bottom 25% of dividend payers in the NZ market (2.85%).

High Dividend: HGH's dividend (6.25%) is in the top 25% of dividend payers in the NZ market (6.04%)

Stable Dividend: HGH's dividend payments have been volatile in the past 10 years.

Growing Dividend: HGH's dividend payments have increased over the past 10 years.

Earnings Coverage: With its reasonable payout ratio (68.2%), HGH's dividend payments are covered by earnings.

Future Dividend Coverage: HGH's dividends in 3 years are forecast to be covered by earnings (76.6% payout ratio).

How experienced are the management team and are they aligned to shareholders interests?

0.4yrs

Average management tenure

Mr. Jeffrey Kenneth Greenslade, also known as Jeff, LLB, serves as Chief Executive Officer of Heartland Group Holdings Ltd. He serves as Non-Independent Non-Executive Director of Heartland Bank Limited and...

Compensation vs Market: Insufficient data to establish whether Jeff's total compensation is reasonable compared to companies of similar size in the NZ market.

Compensation vs Earnings: Insufficient data to compare Jeff's compensation with company performance.

Experienced Management: HGH's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.

Experienced Board: HGH's board of directors are considered experienced (3.9 years average tenure).

Who are the major shareholders and have insiders been buying or selling?

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

NZSE:HGH Recent Insider Transactions by Companies or Individuals

Date	Value	Name	Entity	Role	Shares	Max Price
24 Mar 22	SellNZ$91,455	Laura Byrne	Individual		40,000	NZ$2.29
15 Dec 21	SellNZ$94,600	Laura Byrne	Individual		40,000	NZ$2.36

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.6%.

Top 25 shareholders own 22.8% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
9.83%	Gregory Tomlinson	69,335,936	NZ$122.0m	18.74%	no data
2.12%	Oceania & Eastern Limited	14,933,951	NZ$26.3m	12.56%	100%
1.82%	The Vanguard Group, Inc.	12,849,840	NZ$22.6m	0.32%	no data
1.62%	Philip Carter	11,416,647	NZ$20.1m	0%	no data
1.43%	Accident Compensation Corporation, Asset Management Arm	10,092,152	NZ$17.8m	0%	0.4%
1.31%	Dimensional Fund Advisors LP	9,224,351	NZ$16.2m	-1.3%	no data
1.09%	JPMorgan Chase & Co, Private Banking and Investment Banking Investments	7,676,933	NZ$13.5m	0%	no data
0.92%	Heartland Trust, Endowment Arm	6,475,976	NZ$11.4m	0%	100%
0.65%	Smartshares Limited	4,573,924	NZ$8.1m	0%	1.02%
0.65%	Norges Bank Investment Management	4,566,990	NZ$8.0m	0%	no data
0.47%	Public Trust of New Zealand, Asset Management Arm	3,292,937	NZ$5.8m	0%	9.82%
0.29%	Jeffrey Greenslade	2,020,855	NZ$3.6m	1.39%	no data
0.15%	Christopher Mace	1,070,204	NZ$1.9m	0%	no data
0.11%	Charles Schwab Investment Management, Inc.	759,734	NZ$1.3m	1.93%	no data
0.093%	AXA Investment Managers S.A.	654,526	NZ$1.2m	0%	no data
0.076%	Mary Irvine	532,829	NZ$937.8k	11.11%	no data
0.036%	Andrew Dixson	252,040	NZ$443.6k	5.95%	no data
0.029%	Eaton Vance Management	203,043	NZ$357.4k	0%	no data
0.026%	State Street Global Advisors, Inc.	181,810	NZ$320.0k	0.9%	no data
0.024%	Bruce Irvine	166,573	NZ$293.2k	20.46%	no data
0.022%	Shelley Ruha	158,536	NZ$279.0k	0%	no data
0.022%	Edward Harvey	157,971	NZ$278.0k	6.89%	no data
0.015%	Kathryn Mitchell	108,088	NZ$190.2k	103.6%	no data
0.0093%	Mercer Investments LLC	65,420	NZ$115.1k	0%	no data
0.0078%	American Century Investment Management Inc	55,170	NZ$97.1k	-28.26%	no data

Heartland Group Holdings Limited's employee growth, exchange listings and data sources

Name: Heartland Group Holdings Limited
Ticker: HGH
Exchange: NZSE
Founded: 1875
Industry: Diversified Banks
Sector: Banks
Implied Market Cap: NZ$1.241b
Shares outstanding: 705.32m
Website: https://shareholders.heartland.co.nz

Heartland Group Holdings Limited
Heartland House
Level 3
Auckland
1023
New Zealand

Ticker	Exchange	Primary Security	Security Type	Country	Currency	Listed on
HGH	NZSE (New Zealand Stock Exchange)	Yes	New Ordinary Shares	NZ	NZD	Feb 2011
HGH	ASX (Australian Securities Exchange)	Yes	New Ordinary Shares	AU	AUD	Feb 2011
HGH	CHIA (Chi-X Australia)	Yes	New Ordinary Shares	AU	AUD	Feb 2011
73X	BST (Boerse-Stuttgart)	Yes	New Ordinary Shares	DE	EUR	Feb 2011

All financial data provided by Standard & Poor's Capital IQ.

Data	Last Updated (UTC time)
Company Analysis	2022/09/24 00:00
End of Day Share Price	2022/09/23 00:00
Earnings	2022/06/30
Annual Earnings	2022/06/30

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Q&A What

What is the stock price of hgh

Average management tenure

Pos Terkait

Periklanan

BERITA TERKINI

Toplist Popular

Periklanan

Terpopuler

Periklanan

Tentang Kami

Legal

Dukungan

Social